The Case For and Against Valeant Pharmaceuticals

Here are three reasons for optimism and three reasons for caution.

| More on:
The Motley Fool

Valeant Pharmaceuticals (TSX:VRX)(NYSE: VRX) has been in the news recently based on its interest in Allergan (NYSE: AGN).

Valeant, which has a market cap of more than $40 billion, aspires to become one of the great pharmaceutical companies in the world, rivalling Novartis and Johnson & Johnson. For Valeant to become that big in a relatively short period, it needs to hunt for big elephants to move the needle.

What does this mean for current and potential investors?

Three reasons for optimism

1. Growth potential: Because Valeant wants to be one of the great pharma companies, it will continue to grow aggressively via merger and acquisitions. It has grown at an average compound annual growth rate of 23.1% per year from 2004-2013 and as a result, its shareholders have been well rewarded, beating both the S&P 500 and TSX during the same time period.

2. It’s not really a pharma business: Historically, the industry can be broadly divided into three categories — pharmaceuticals (high risk/high reward), over-the-counter (lower margin, but repeat business), and medical equipment (decent margins, incremental innovations). For Valeant to succeed, it cannot afford the significant money needed for research and development as it needs sustainable cash flows to cover debt. Thus, Valeant is transforming itself into a more of a consumer packaged goods business model, where cash flows will be more predictable.

3. Valuation matters: Valeant currently trades between 13.5 to 14 estimated 2014 forward price-to-earnings (PE) ratio and 12 to 12.5 estimated 2015 forward PE. This would imply that Valeant is trading at a PE range that is on average, near the lower end of historic market averages, making it a decent valuation.

Three reasons for caution

1. High debt needed to finance future growth: With recent string of acquisitions, including the acquisition of Bausch + Lomb in 2013, Valeant’s long-term debt to assets ratio is now a whopping 61.4% as of 2013, up from 18.4% as of 2009. Comparatively, Novartis has a long-term debt to asset ratio of 8.9% as of 2013 (Johnson and Johnson’s is slightly higher).

2. If you are not using debt, you are using equity: Now, if you are not using debt to finance large acquisitions, you pretty much have to use equity. It is very painful for shareholders to see equity being used given the relatively low-interest environment.

3. Making mergers work is a tough business: Given its size, Valeant needs to hunt for bigger and bigger targets to achieve meaningful growth. Given the historical high probability of merger and acquisition failures, there is enormous risk. On average, merger and acquisitions have a less than 50% chance of succeeding. And it just takes one bad acquisition for shareholders to lose significant value.     

Ultimately, investors need to balance the opportunities and risks. While Valeant delivered significant shareholder value over the past years, its aggressiveness to grow via merger and acquisitions may ultimately pose significant risk for investors.

 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Patrick Li, CPA, CMA has a position in Johnson and Johnson. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Johnson & Johnson and Valeant Pharmaceuticals.

More on Investing

Canadian Dollars
Stocks for Beginners

3 Stocks to Invest $30,000 in Right Now

Are you looking for some of the best stocks to invest in right now? Here's a trio that offer growth…

Read more »

Businessmen teamwork brainstorming meeting.
Dividend Stocks

1 Magnificent Dividend Stock Down 15% to Buy and Hold Forever

Enbridge is off the 12-month lows but still trades at a large discount to its 2022 high.

Read more »

Male IT Specialist Holds Laptop and Discusses Work with Female Server Technician. They're Standing in Data Center, Rack Server Cabinet with Cloud Server Icon and Visualization
Tech Stocks

Missed Out on NVIDIA? My Best Growth Stock Pick to Buy and Hold

A TSX growth stock is a top pick and profitable investment choice if you missed out on the ascent of…

Read more »

Increasing yield
Dividend Stocks

My Top 5 Ultra-High-Yield Dividend Stocks to Buy in May

If you’re looking to build a passive-income stream, these five dividend stocks should be on your radar.

Read more »

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Friday, May 24

The main TSX index seems on track to end the week in the red as it currently trades with 1.2%…

Read more »

consider the options
Bank Stocks

Is TD Bank Stock the Best Bank Stock for You?

TD Bank stock is reflecting a lot of the negative news. It remains a top bank stock trading at attractive…

Read more »

Payday ringed on a calendar
Dividend Stocks

A 10.6% Dividend Stock That Provides Monthly Cash Payments

A dividend stock with a mouth-watering yield providing monthly cash flow streams.

Read more »

Businessman holding AI cloud
Tech Stocks

Ready to Invest in Artificial Intelligence (AI)? 2 Stocks That Are Solid Bets

These two AI stocks provide investors with strong future opportunities as AI continues to become a part of our everyday…

Read more »